ICH Q10 may replace FDA's Quality System guidance
This article was originally published in The Gold Sheet
Executive Summary
FDA official Diana Amador-Toro reported that the ICH guideline is "a model for an effective quality system" and is necessary to harmonize the "divergent approaches to quality systems across regions and to correct suboptimal deployment of resources by both industry and regulators." It is also needed to correct the "inconsistent approaches to compliance inspections," she noted on July 24 at the Pharma Conference. Amador-Toro is on the committee negotiating ICH Q10, which was approved as a Step 2 guidance in the U.S. and the EU in May. It is unclear whether it has yet been approved in Japan; Amador-Toro noted that translation problems may be delaying its approval there. The guideline focuses on management responsibility of the quality system, continual improvement of the process performance, and continual improvement of the pharmaceutical quality system. Amador-Toro said that she was "amazed at the [quality system] differences between the three regions. [The guideline] shows our common commitment to quality and encourages a preventive action culture." Amador-Toro reported that the ICH expert working group will start to work on a Step 3 guidance in June 2008 after the close of the public comment period for the Step 2 guidance. "I encourage you all to submit your comments," she told meeting participant
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.